Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Motor imaging vs usual care Phantom limb pain frequency · people with transtibial amputation due to peripheral arterial disease or diabetes Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Gait training protocol focused on impairment level vs gait training protocol focused on task level Mortality – all cause · people with transtibial amputation due to peripheral arterial disease or diabetes Interventions for motor rehabilitation in people with transtibial amputation due to peripheral arterial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Intralesional classical immunosuppresants (betamethasone or triamcinolone) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral small molecule inhibitors (ruxolitinib) vs oral small molecule inhibitors (tofacitinib) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical small molecule inhibitors (ruxolitinib) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo Incidence of serious adverse events ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil) Incidence of serious adverse events ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone or squaric acid dibutil ester) vs hair growth stimulants (minoxidil) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Contact immunotherapy (diphencyprone) + hair growth stimulants (minoxidil) vs contact immunotherapy (diphencyprone) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical hair growth stimulants (minoxidil) vs placebo Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Topical hair growth stimulants (minoxidil) vs placebo Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Other therapies (cryotherapy) vs other therapies (fractional CO2 laser) Long‐term hair regrowth ≥ 75% ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone) Health‐related quality of life ‐ not reported · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Oral classical immunosuppressants (betamethasone) vs oral classical immunosuppressants (azathioprine, methotrexate, prednisolone) Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata Treatments for alopecia areata: a network meta‐analysis (2023) · Cochrane | no estimate extracted | NR | No studies |
Digital technology (TIM) vs standard treatment (TBM) Treatment burden · children aged 5 to 16 years Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Digital technology (TIM) vs standard treatment (TBM) QoL · children aged 5 to 16 years Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Digital technology (TIM) vs standard treatment (TBM) Number of pulmonary exacerbations · children aged 5 to 16 years Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard‐protein formula vs low‐protein formula Overweight · healthy, full‐term (37 to 42 weeks), formula‐fed infants Higher versus lower protein intake in formula‐fed term infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard‐protein formula vs low‐protein formula Obesity · healthy, full‐term (37 to 42 weeks), formula‐fed infants Higher versus lower protein intake in formula‐fed term infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Standard‐protein formula vs low‐protein formula All‐cause mortality · healthy, full‐term (37 to 42 weeks), formula‐fed infants Higher versus lower protein intake in formula‐fed term infants (2023) · Cochrane | no estimate extracted | NR | No studies |
High‐protein formula vs standard‐protein formula All‐cause mortality · healthy, full‐term, formula‐fed infants Higher versus lower protein intake in formula‐fed term infants (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I and/or III antiarrhythmics vs control Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I antiarrhythmics vs control Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I antiarrhythmics vs control Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I antiarrhythmics vs control Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I antiarrhythmics vs control All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class III antiarrhythmics vs control Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class III antiarrhythmics vs control Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class III antiarrhythmics vs control Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I and/or III antiarrhythmics vs control Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Class I antiarrhythmics vs control Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial… (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: psychological interventions vs an active comparator Treatment‐related adverse events Anxiety · adults (aged 16 years and over) with CF Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: psychological interventions vs an active comparator Treatment‐related adverse events Depression · adults (aged 16 years and over) with CF Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · Cochrane | no estimate extracted | NR | No studies |
Single foetal haemoglobin inducer at any dose or duration vs usual care or placebo Frequency of transfusion (transfused volume/year) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
Single foetal haemoglobin inducer at any dose or duration vs another foetal haemoglobin inducer QoL · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer Frequency of transfusion (transfused volume/ year) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer Transfusion‐free interval (days) · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |
One dose or dose regimen of a foetal haemoglobin inducer vs another dose or dose regimen of the same foetal haemoglobin inducer QoL · people with non‐transfusion‐dependent β‐thalassaemia Foetal haemoglobin inducers for reducing blood transfusion in non‐transfusion‐dependent beta‐thalassaemias (2023) · Cochrane | no estimate extracted | NR | No studies |